SCHEMBL23389232

SCHEMBL23389232

CC(C)(C)OC(=O)NC1CCCN(C(=O)c2cc3cc(OC(F)(F)F)c(F)cc3[nH]2)C1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ PARP1 P09874 3/20 0.42
▸ BRD4 O60885 1/20 0.41
▸ HRH4 Q9H3N8 2/20 0.39
▸ HRH3 Q9Y5N1 1/20 0.39
▸ DDR1 Q08345 2/20 0.39
▸ NTRK1 P04629 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ ADORA2A P29274 1/20 0.38
▸ ADORA2B P29275 1/20 0.38
▸ AURKA O14965 3/20 0.37
▸ PDPK1 O15530 3/20 0.37
▸ AURKB Q96GD4 3/20 0.37
▸ PADI4 Q9UM07 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23389233 1.00 KMT2A (0.46) KMT2AMEN1CA1CA2PARP1
SCHEMBL23419030 0.86 FPR2 (0.39) KMT2AMEN1PARP1BRD4HRH4
SCHEMBL29943528 0.86 FPR2 (0.39) KMT2AMEN1PARP1BRD4HRH4
SCHEMBL23389181 0.85 KMT2A (0.51) KMT2AMEN1CA1CA2PARP1
SCHEMBL29943552 0.85 KMT2A (0.51) KMT2AMEN1CA1CA2PARP1
SCHEMBL23389178 0.85 KMT2A (0.51) KMT2AMEN1CA1CA2PARP1
SCHEMBL23419031 0.82 KDM4D (0.38) CA1CA2PARP1DDR1AURKA
SCHEMBL23389209 0.81 KMT2A (0.47) KMT2AMEN1PARP1HRH4HRH3
SCHEMBL23389212 0.81 KMT2A (0.47) KMT2AMEN1PARP1HRH4HRH3
SCHEMBL29944026 0.81 KMT2A (0.47) KMT2AMEN1PARP1HRH4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263366-A2 CASPASE 6 INHIBITORS AND USES THEREOF SHANGPHARMA INNOVATION INC. 2025-08-21 — — US disclosed
US-20230202974-A1 CASPASE 6 INHIBITORS AND USES THEREOF UNIV CALIFORNIA (US) 2023-06-29 — — US disclosed
WO-2021102361-A1 CASPASE 6 INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-05-27 — — WO disclosed
WO-2021102361-A1 CASPASE 6 INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202974-A1 CASPASE 6 INHIBITORS AND USES THEREOF CASP6, CASP1, CASP10 KMT2A 4587/4885MEN1 4223/4885CA1 1633/4885
US-20250263366-A2 CASPASE 6 INHIBITORS AND USES THEREOF CASP6, CASP1, CASP10 KMT2A 4587/4885MEN1 4223/4885CA1 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback